Replies to post #48864 on Biotech Values

[rfj1862]

>Valuation wise which one is cheaper<

XNPT: 1) The RLS market is a bigger opportunity than developing yet another drug for PHN; 2) Remember that they have a baclofen analog in development as well; this is a potential billion-dollar drug.

I own neither, but I did own XNPT.